PE20151140A1 - Pirazoles sustituidos como bloqueadores del canal de calcio tipo n - Google Patents

Pirazoles sustituidos como bloqueadores del canal de calcio tipo n

Info

Publication number
PE20151140A1
PE20151140A1 PE2015000208A PE2015000208A PE20151140A1 PE 20151140 A1 PE20151140 A1 PE 20151140A1 PE 2015000208 A PE2015000208 A PE 2015000208A PE 2015000208 A PE2015000208 A PE 2015000208A PE 20151140 A1 PE20151140 A1 PE 20151140A1
Authority
PE
Peru
Prior art keywords
calcium channel
channel blockers
type calcium
pyrazoles
substitute
Prior art date
Application number
PE2015000208A
Other languages
English (en)
Inventor
Mark Wall
Nalin Subasinghe
Zhihua Sui
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49036655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151140(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20151140A1 publication Critical patent/PE20151140A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La invencion se refiere a compuestos de la Formula (I), utiles como el bloqueadores del canal de calcio tipo N, donde: X1, X2, X3, y X4 son CH o N; n es 0,1 o 2; R1 es alquilo de C1-4, alcoxi de C1-4 di(alquilo de C1-4) amino, entre otros; R2 es alcoxi de C1-4, halo, o trifluorometilo; R3 es hidrogeno o bromo; el anillo A se selecciona del grupo que consiste en piridina-N-oxido, benzo[1,3]dioxol-5-ilo, 4,4-dimetilciclohex-1-en-1-ilo, indolilo, 1-metil-indolilo, entre otros; Q es Q1, Q2, Q3, entre otros
PE2015000208A 2012-08-16 2013-08-16 Pirazoles sustituidos como bloqueadores del canal de calcio tipo n PE20151140A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261683777P 2012-08-16 2012-08-16

Publications (1)

Publication Number Publication Date
PE20151140A1 true PE20151140A1 (es) 2015-08-07

Family

ID=49036655

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000208A PE20151140A1 (es) 2012-08-16 2013-08-16 Pirazoles sustituidos como bloqueadores del canal de calcio tipo n

Country Status (19)

Country Link
US (1) US8901314B2 (es)
EP (1) EP2885293B1 (es)
JP (2) JP2015524852A (es)
KR (1) KR20150042834A (es)
CN (2) CN104903316B (es)
AU (2) AU2013302471B2 (es)
BR (1) BR112015003395A2 (es)
CA (1) CA2882123C (es)
CL (1) CL2015000358A1 (es)
CR (1) CR20150069A (es)
EA (1) EA201590380A1 (es)
ES (1) ES2600743T3 (es)
HK (1) HK1214860A1 (es)
IL (1) IL237191A0 (es)
MX (1) MX2015002038A (es)
PE (1) PE20151140A1 (es)
PH (1) PH12015500315A1 (es)
SG (1) SG11201501137VA (es)
WO (1) WO2014028803A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6262732B2 (ja) 2012-08-16 2018-01-17 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル遮断剤としての置換ピラゾール
US10202350B2 (en) 2015-06-12 2019-02-12 Vettore, LLC MCT4 inhibitors for treating disease
KR101743960B1 (ko) 2015-07-06 2017-06-08 서울대학교산학협력단 G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
JP2019518017A (ja) * 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
KR102573333B1 (ko) 2016-06-28 2023-08-31 삼성디스플레이 주식회사 표시 장치
MX2019006893A (es) * 2016-12-12 2019-10-09 Vettore Llc Inhibidores heterociclicos de mct4.
EP3703676A4 (en) 2017-11-04 2021-12-15 Advanced Proteome Therapeutics, Inc. COMPOSITION AND PROCESS FOR MODIFYING POLYPEPTIDES
JP6800492B2 (ja) * 2018-06-29 2020-12-16 ＭｉＺ株式会社 水素を含む癌性疼痛の抑制もしくは軽減のための組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1998054123A1 (en) * 1997-05-30 1998-12-03 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
US20020077328A1 (en) * 2000-07-13 2002-06-20 Fred Hassan Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
JP4537855B2 (ja) * 2002-10-09 2010-09-08 久光製薬株式会社 抗真菌活性を有する新規ピラゾール化合物
AU2004243511A1 (en) * 2003-05-30 2004-12-09 Neuromed Technologies, Inc 3-aminomethyl-pyrrolidines as N-type calcium channel blockers
AU2006331963A1 (en) * 2005-12-22 2007-07-05 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
MX2010009652A (es) * 2008-03-11 2010-09-30 Danisco Us Inc Glucoamilasa y fitasa de buttiauxella durante la sacarificacion.
JP5421368B2 (ja) * 2008-08-01 2014-02-19 パーデュー、ファーマ、リミテッド、パートナーシップ テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
HK1214860A1 (zh) 2016-08-05
MX2015002038A (es) 2016-01-22
EA201590380A1 (ru) 2015-07-30
PH12015500315A1 (en) 2015-03-30
AU2017261551A1 (en) 2017-12-07
CN107857757A (zh) 2018-03-30
CA2882123A1 (en) 2014-02-20
EP2885293A1 (en) 2015-06-24
US20140163031A1 (en) 2014-06-12
ES2600743T3 (es) 2017-02-10
IL237191A0 (en) 2015-04-30
JP6294559B1 (ja) 2018-03-14
US8901314B2 (en) 2014-12-02
CN104903316A (zh) 2015-09-09
KR20150042834A (ko) 2015-04-21
BR112015003395A2 (pt) 2017-07-04
SG11201501137VA (en) 2015-04-29
JP2015524852A (ja) 2015-08-27
AU2013302471B2 (en) 2017-08-17
CR20150069A (es) 2015-05-18
JP2018065865A (ja) 2018-04-26
CN104903316B (zh) 2017-11-28
EP2885293B1 (en) 2016-07-27
WO2014028803A1 (en) 2014-02-20
AU2017261551B2 (en) 2019-07-04
CL2015000358A1 (es) 2015-06-12
AU2013302471A1 (en) 2015-02-26
CA2882123C (en) 2021-07-20

Similar Documents

Publication Publication Date Title
PE20151140A1 (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
CL2020003007A1 (es) Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017)
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
PE20150684A1 (es) Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
SV2011003831A (es) Compuestos organicos
PE20160546A1 (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
CR11524A (es) Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
BR112014030473A2 (pt) novo diazaespirocicloalcano e azaespirocicloalcano
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
ECSP11011244A (es) Nuevos herbicidas.
PE20141821A1 (es) Composiciones herbicidas que contienen bentazon y el inhibidor als y el inhibidor accasa
PE20151138A1 (es) Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n
PE20151139A1 (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
AR084173A1 (es) Derivados oxazolil-metileter como agonistas del receptor alx
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
PE20151977A1 (es) Nuevos derivados de purina
PE20151158A1 (es) Moduladores selectivos del receptor de androgenos novedosos

Legal Events

Date Code Title Description
FD Application declared void or lapsed